请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
℡ 4000-520-616
℡ 4000-520-616
MedKoo/TG101209newfeatured/25mg/406190
产品编号:406190
市  场 价:¥1800.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$90.00
品      牌: MedKoo
公      司:MedKoo Biosciences, Inc
公司分类:
MedKoo/TG101209newfeatured/25mg/406190
商品介绍

TG101209
new
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406190

CAS#:936091-14-4

Description:TG101209 is a novel and potent JAK2 inhibitor, which induced dose- and time-dependent cytotoxicity in a variety of multiple myeloma (MM) cell lines. The induction of cytotoxicity was associated with inhibition of cell cycle progression and induction of apoptosis in myeloma cell lines and patient-derived plasma cells. Exploring the mechanism of action of TG101209 indicated downregulation of pJak2, pStat3, and Bcl-xl levels with upregulation of pErk and pAkt levels indicating cross talk between signaling pathways. TG101209 , when used in combination with the PI3K inhibitor LY294002, demonstrated synergistic cytotoxicity against myeloma cells.

Price and Availability

SizePriceShipping out timeQuantity
25mgUSD 90Same day
50mgUSD 150Same day
100mgUSD 250Same day
200mgUSD 450Same day
500mgUSD 950Same day
1gUSD 1650Same day
2gUSD 2850Same day
5gUSD 42502 Weeks
10gUSD 76502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

TG101209, purity > 98%, is in stock. The same day shipping after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406190Name: TG101209CAS#: 936091-14-4Chemical Formula: C26H35N7O2SExact Mass: 509.25729Molecular Weight: 509.67Elemental Analysis: C, 61.27; H, 6.92; N, 19.24; O, 6.28; S, 6.29

Synonym:TG101209; TG-101209; TG 101209

IUPAC/Chemical Name:N-tert-butyl-3-(5-methyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide

InChi Key:JVDOKQYTTYUYDV-UHFFFAOYSA-N

InChi Code:InChI=1S/C26H35N7O2S/c1-19-18-27-25(29-20-9-11-22(12-10-20)33-15-13-32(5)14-16-33)30-24(19)28-21-7-6-8-23(17-21)36(34,35)31-26(2,3)4/h6-12,17-18,31H,13-16H2,1-5H3,(H2,27,28,29,30)

SMILES Code:O=S(C1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC=C2C)=C1)(NC(C)(C)C)=O

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#CRB60831

QC Data:
View QC data: current batch, Lot#CRB60831

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Sun Y, Moretti L, Giacalone NJ, Schleicher S,Speirs CK, Carbone DP, Lu B. Inhibition of JAK2 signaling by TG101209enhances radiotherapy in lung cancer models. J Thorac Oncol. 2011Apr;6(4):699-706. doi: 10.1097/JTO.0b013e31820d9d11. PubMed PMID:21325979; PubMed Central PMCID: PMC3104103.

2: Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T,Pardanani A, Tefferi A, Rajkumar SV, Kumar S. TG101209, a novel JAK2inhibitor, has significant in vitro activity in multiple myeloma anddisplays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol.2010 Sep;85(9):675-86. doi: 10.1002/ajh.21785. PubMed PMID: 20652971;PubMed Central PMCID: PMC2940994.

3: Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A,Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P,Levine RL, Bhalla KN. Cotreatment with panobinostat and JAK2 inhibitorTG101209 attenuates JAK2V617F levels and signaling and exertssynergistic cytotoxic effects against human myeloproliferativeneoplastic cells. Blood. 2009 Dec 3;114(24):5024-33. doi:10.1182/blood-2009-05-222133. Epub 2009 Oct 14. PubMed PMID: 19828702;PubMed Central PMCID: PMC2788976.

4: Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, FinkeC, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. TG101209, asmall molecule JAK2-selective kinase inhibitor potently inhibitsmyeloproliferative disorder-associated JAK2V617F and MPLW515L/Kmutations. Leukemia. 2007 Aug;21(8):1658-68. Epub 2007 May 31. PubMedPMID: 17541402.

品牌介绍
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔